Krystal Biotech Files Response With USPTO on KB801 Patent Application; Discontinues Clinical Study To Advance KB801 Into Pivotal Trial; No Safety Concerns Observed; No Further Subject-level Updates From Discontinued Study; Pivotal Trial Results Expected In Due Course

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

Krystal Biotech announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will participate in a fireside chat at 3:55 pm ET and host investor meetings. The company reported strong Q2 2026 results with $119.2 million in VYJUVEK global revenue and $965.9 million in cumulative revenue since launch, with plans for European expansions and multiple clinical data readouts expected in the second half of 2026.

RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.

Krystal Biotech shares are trading lower after the company announced mixed Q2 financial results.